



Atty. Docket No. 1510-1030

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Lars LANNFELT

Confirmation No. 9645

Serial No. 09/899,815

GROUP 1646

Filed July 9, 2001

Examiner O. Chernyshev

PREVENTION AND TREATMENT OF

ALZHEIMER'S DISEASE

AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Official Action of November 19, 2002,
please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 1, between lines 1 and 2, add the following
paragraph:

--This application claims priority to United States
provisional application No. 60/217,098.--

Page 5, replace the last full paragraph as follows:

--The A β -Arc as disclosed in SEQ ID NO:1. A β -Arc
comprises 39, 40 or 42 amino acids but may also be shorter as
long as the protofibril forming ability is maintained.--

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

Page 7, replace the third full paragraph as follows:

ε³
--In yet a further aspect, the invention relates to antibodies against the A β peptide of SEQ ID NO:1. The antibodies may be monoclonal or polyclonal or antibody fragments. Preferably the antibodies are humanized for use in passive immunisation for prevention of therapy against AD. Thus, antibodies which react with the unique epitope created by glycine at condon 693 are provided.--

Page 12, replace the last full paragraph, bridging page 13, as follows:

ε⁴
--The effect of the Arctic mutation on A β formation was further investigated *in vitro* in transiently transfected HEK293 cells. APPwt was compared to the following mutations: Arctic (APP_{E693G}), Dutch (APP_{E693Q}), Italian (APP_{E693K}) and Flemish (APP_{A692G}). Constructs containing the Swedish double mutation (APP_{Swe}) and one APP mutation at codon 717 (APP_{V717F}), both with well-studied APP processing characteristics (Hardy (1997)), were used as positive controls. The mutations were introduced to APP695 cDNA in pcDNA3 using QUICKCHANGETM Site-Directed Mutagenesis Kit according to the manufacturers instructions (Stratagene). The mutated constructs were verified by sequencing. For the ELISA measurements, HEK293 cells were seeded in six-well dishes and transfected with the different constructs using FUGENETM 6 Transfection Reagent (Roche Diagnostics) according to the manufacturers instructions. 24 h